News|Articles|August 27, 2026

Five Key Posters From the 2026 SNO/ASCO CNS Metastases Conference

Fact checked by: Tim Cortese, Russ Conroy

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

The 2026 SNO/ASCO CNS Metastases Conference brought together a multidisciplinary audience of neuro-oncologists, radiation oncologists, neurosurgeons, medical oncologists, and translational researchers to address the growing burden of brain and leptomeningeal metastases across tumor types. The meeting highlighted basic and translational research into central nervous system (CNS) tropism and the metastatic microenvironment alongside clinical sessions on precision neurosurgery, modern radiotherapy techniques, and the integration of systemic and CNS-directed therapies.